Acticor: repositioning in myocardial infarction

(CercleFinance.com) - Acticor Biotech shares soared on the Paris Bourse on Monday, after the biopharmaceutical company declared its intention to reposition itself in the treatment of myocardial infarction.


Shortly before 12.15pm, the share price climbed 45%, making it the second-biggest gainer on the Paris market behind Inventiva.

In a press release issued on Friday evening, Acticor said it was currently conducting a Phase 2b study, in partnership with the University of Birmingham in the UK, to assess the efficacy and safety of glenzocimab, its humanized monoclonal antibody fragment, in reducing infarct size and preventing microvascular complications.

The study is expected to enroll over 212 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

The aim of the study is to assess the safety and efficacy of glenzocimab 1000 mg, compared with placebo, in reducing myocardial infarct size after 90 days.

To date, 27 patients have been enrolled, with results expected in Q4 2026.

In parallel, a Phase 2 study to evaluate glenzocimab in the treatment of myocardial infarction is currently being prepared, with the aim of enrolling around 300 patients in cardiac intensive care units.

The primary objective of the study is to evaluate the efficacy of glenzocimab in reducing the surface area of myocardial infarction at day 90 after PCI (Percutaneous Coronary Intervention), as well as its safety.

The study envisages testing several dose levels and optimizing the mode of administration to make it more compatible with the timeframes of this emergency procedure.

The aim is to provide all the clinical and regulatory data required for a phase 3 trial, with a view to possible registration as early as 2027.

Patient recruitment could begin in Q1 2025, subject to financing of the company, which is currently in receivership.

At the same time, Acticor Biotech has announced the appointment of François Guillet as CFO, an executive who has worked for several tech companies such as Oracle and Adobe.

Copyright (c) 2024 CercleFinance.com. All rights reserved.